News Releases

August 13, 2019
Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 13, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal
Additional Formats
August 6, 2019
Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Aug. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter
Additional Formats
June 3, 2019
Urovant Sciences to Present at Annual Roivant Pipeline Day
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Jun. 3, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced Chief Executive Officer Keith A.
Additional Formats
Displaying 1 - 10 of 19